Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;25(3):219-233.
doi: 10.2174/0113895575309785240902102421.

Development of Mycobacterium tuberculosis Enoyl Acyl Reductase (InhA) Inhibitors: A Mini-Review

Affiliations
Review

Development of Mycobacterium tuberculosis Enoyl Acyl Reductase (InhA) Inhibitors: A Mini-Review

Navin Kumar Tailor et al. Mini Rev Med Chem. 2025.

Abstract

This review article delves into the critical role of Enoyl acyl carrier protein reductase (InhA; ENR), a vital enzyme in the NADH-dependent acyl carrier protein reductase family, emphasizing its significance in fatty acid synthesis and, more specifically, the biosynthesis of mycolic acid. The primary objective of this literature review is to elucidate diverse scaffolds and their developmental progression targeting InhA inhibition, thereby disrupting mycolic acid biosynthesis. Various scaffolds, including thiourea, piperazine, thiadiazole, triazole, quinazoline, benzamide, rhodanine, benzoxazole, and pyridine, have been systematically explored for their potential as InhA inhibitors. Noteworthy findings highlight thiadiazole and triazole derivatives, demonstrating promising IC50 values within the nanomolar concentration range. The review offers comprehensive insights into InhA's structure, structure-activity relationships, and a detailed overview of distinct scaffolds as effective inhibitors of InhA.

Keywords: InhA inhibitors; Mycobacterium tuberculosis; antitubercular agents; enoyl acyl carrier protein reductase; first-line drug regimens; tuberculosis..

PubMed Disclaimer

References

    1. Prasad M.S.; Bhole R.P.; Khedekar P.B.; Chikhale R.V.; Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery. Bioorg Chem 2021,115,105242 - DOI - PubMed
    1. Jee B.; Understanding the early host immune response against Mycobacterium tuberculosis. Cent Eur J Immunol 2020,45(1),99-103 - DOI - PubMed
    1. Burki T.; Tuberculosis mortality targets off-track. Lancet Infect Dis 2019,19(5),472 - DOI - PubMed
    1. Lin C.H.; Lin C.J.; Kuo Y.W.; Wang J.Y.; Hsu C.L.; Chen J.M.; Cheng W.C.; Lee L.N.; Tuberculosis mortality: Patient characteristics and causes. BMC Infect Dis 2014,14(1),5 - DOI - PubMed
    1. Denholm J.T.; Marais B.J.; Donnan E.J.; Waring J.; Stapledon R.; Taylor J.W.; Mahanty S.; Tuberculosis mortality: Quantifying agreement in clinical cause of death assessments. Aust N Z J Public Health 2022,46(5),630-632 - DOI - PubMed

MeSH terms

LinkOut - more resources